Clareo Health | Impact on Mortality of Screening for Kidney Disease Associated With a Specialized Intervention During Hospitalization in a Territorial Hospital Trust
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire de Nīmes
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient or their representative must have given their free and informed consent oral consent
The patient must be a member or beneficiary of a health insurance plan
Patient living in the Gard, France
Patient with abnormal dose:
* Severe grade 4 or 5 CKD suspected in front of a GFR \<30 mL / min / 1.73m2 persisting during hospitalization.
* Acute kidney injury \> stage 1 defined by an increase in serum creatinine of at least 100% in less than 7 days or a threshold greater than 354 µmol / l.
You may not be if
The subject is participating in another category I interventional study, or is in a period of exclusion determined by a previous study
It is impossible to give the subject or their representative informed information
The patient is under safeguard of justice or state guardianship
Patient is pregnant, parturient or breastfeeding.
Patient unable to express consent
Patient with Stage 1 Acute kidney injury defined by an increase in serum creatinine of more than 26 µmol / l in less than 48 hours or a 50% increase in serum creatinine within 7 days.
Patient with stage 1 to 3 CKD (glomerular filtration rate (GFR)\> 30 mL / min / 1.73m2)
* Palliative/end-of-life patients
* Patients who died within 72 hours of receiving the signal
* Patients hospitalized in nephrology after an emergency room visit only
